Every article, report, and earnings note where NTRA appears.
Natera, Inc. (NTRA) jumps after hours after posting strong Q2 revenue growth, raising full-year guidance, and drawing higher price targets from major analysts. The move pushed the stock above its 52-week high, but investors should watch whether regular-session trading confirms the breakout.
Natera posted 39% Q1 revenue growth and continued rapid oncology and women’s health expansion, but losses and a rich valuation keep the stock at Hold. The report sees strong long-term clinical momentum, yet limited margin of safety at the current price.
Natera, Inc. (NTRA) jumps sharply after hours as investors react to its upcoming earnings event and strong recent operating momentum. The diagnostics company has posted rapid revenue growth, rising test volumes, and higher analyst targets, but the stock’s premium valuation means the move still needs confirmation in regular trading.
Freenome, Inc. Common stock (NASDAQ: FRNM) is expected to list on 2026-07-21, but the price range has not been disclosed yet. The company is going public through a SPAC merger with Perceptive Capital Solutions Corp., not a traditional IPO. Bulls will focus on the 2026 launch plan and large healthcare-investor PIPE; bears will focus on heavy losses and a still-unproven commercialization path.
Generate an AI-powered research report — grades, price targets, financials, and chart analysis on demand.
Generate NTRA ReportCancel anytime